Senti Biosciences (SNTI) Projected to Release Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Senti Biosciences to announce earnings of ($0.21) per share and revenue of $0.02 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). The firm had revenue of $0.02 million for the quarter. On average, analysts expect Senti Biosciences to post ($1.53) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Senti Biosciences Stock Performance

SNTI opened at $0.14 on Wednesday. Senti Biosciences has a fifty-two week low of $0.14 and a fifty-two week high of $2.88. The company’s 50-day moving average is $0.27 and its 200 day moving average is $0.69.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Senti Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Company Profile

Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.